Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma is set to commence the production of clinical batches of Livatag (doxorubicin Transdrug) for Phase III trial in liver cancer.
Subscribe to our email newsletter
Livatag, which has been awarded orphan drug status in Europe and US, is a treatment presented in nanoparticles able to deliver doxorubicin in chemoresistant cells.
The production for injectable cytotoxic products in nanoparticle form is expected to be done by the companies who have expertise in production of nanoparticles.
BioAlliance Pharma claims its team specialized in industrial development will collaborate with its partners throughout the process to ensure the transmission of its know-how specific to nanoparticle Transdrug technology.
BioAlliance CEO Judith Greciet said the BioAlliance Pharma’s industrial development team and its European partners have been committed to prepare the clinical production of Livatag, relying on their specific nanotechnology expertise and know-how.